Feng Zhou1, Yukai Liu1, Hongchao Shi1, Qing Huang1, Junshan Zhou2. 1. Nanjing First Hospital, Nanjing Medical University, Nanjing, China. 2. Nanjing First Hospital, Nanjing Medical University, Nanjing, China. sjnk806@126.com.
Abstract
BACKGROUND: Manifestations of ischemic stroke vary widely, and serum biomarkers may be useful for stratification of risk of severe stroke. This study evaluated the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and initial severity. METHODS: We employed a retrospective analysis on our hospital-based registry and recruited 488 first-onset ischemic stroke patients admitted within 24 h after onset and with Lp-PLA2 mass measured. Stroke severities evaluated by National Institutes of Health Stroke Scale (NIHSS) were compared between Lp-PLA2 categories dichotomized by median. Multivariate logistic regression was used to detect the independent risk factors of severe stroke (NIHSS ≥ 7) and receiver operator curve (ROC) was constructed to detect the value of addition of Lp-PLA2 to the model of other risk factors for predicting severe stroke. RESULTS: Of the overall patients, the median admission NIHSS scores was 3 and 28.1% had severe manifestation. Admission NIHSS scores were different between patients of Lp-PLA2 above and under the median (median NIHSS 4 vs. 3, P < 0.001). Lp-PLA2 levels was correlated with admission NIHSS (r = 0.268, P < 0.001). Logistic regression showed Lp-PLA2 category (OR 2.37, 95%CI 1.44-3.90, P < 0.001) and levels per 100 ng/ml (OR 1.69, 95%CI 1.35-2.11, P < 0.001) were both independently associated with severe stroke. Addition of Lp-PLA2 category and levels to other independent risk factors both increased the area under curves (from 0.676 to 0.718 with category and 0.734 with levels). CONCLUSION: Lp-PLA2 was independently related to admission severity in ischemic stroke patients, implying a potential predictive value of Lp-PLA2 for severe stroke in prevention.
BACKGROUND: Manifestations of ischemic stroke vary widely, and serum biomarkers may be useful for stratification of risk of severe stroke. This study evaluated the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and initial severity. METHODS: We employed a retrospective analysis on our hospital-based registry and recruited 488 first-onset ischemic strokepatients admitted within 24 h after onset and with Lp-PLA2 mass measured. Stroke severities evaluated by National Institutes of Health Stroke Scale (NIHSS) were compared between Lp-PLA2 categories dichotomized by median. Multivariate logistic regression was used to detect the independent risk factors of severe stroke (NIHSS ≥ 7) and receiver operator curve (ROC) was constructed to detect the value of addition of Lp-PLA2 to the model of other risk factors for predicting severe stroke. RESULTS: Of the overall patients, the median admission NIHSS scores was 3 and 28.1% had severe manifestation. Admission NIHSS scores were different between patients of Lp-PLA2 above and under the median (median NIHSS 4 vs. 3, P < 0.001). Lp-PLA2 levels was correlated with admission NIHSS (r = 0.268, P < 0.001). Logistic regression showed Lp-PLA2 category (OR 2.37, 95%CI 1.44-3.90, P < 0.001) and levels per 100 ng/ml (OR 1.69, 95%CI 1.35-2.11, P < 0.001) were both independently associated with severe stroke. Addition of Lp-PLA2 category and levels to other independent risk factors both increased the area under curves (from 0.676 to 0.718 with category and 0.734 with levels). CONCLUSION:Lp-PLA2 was independently related to admission severity in ischemic strokepatients, implying a potential predictive value of Lp-PLA2 for severe stroke in prevention.
Authors: Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: Mirjam R Heldner; Christoph Zubler; Heinrich P Mattle; Gerhard Schroth; Anja Weck; Marie-Luise Mono; Jan Gralla; Simon Jung; Marwan El-Koussy; Rudolf Lüdi; Xin Yan; Marcel Arnold; Christoph Ozdoba; Pasquale Mordasini; Urs Fischer Journal: Stroke Date: 2013-03-07 Impact factor: 7.914
Authors: Thanh G Phan; Benjamin Clissold; John Ly; Henry Ma; Chris Moran; Velandai Srikanth Journal: J Stroke Cerebrovasc Dis Date: 2016-01-18 Impact factor: 2.136
Authors: Mitchell S V Elkind; Wanling Tai; Kristen Coates; Myunghee C Paik; Ralph L Sacco Journal: Cerebrovasc Dis Date: 2008-11-15 Impact factor: 2.762
Authors: Paweł Burchardt; Jakub Zurawski; Bartosz Zuchowski; Tomasz Kubacki; Dawid Murawa; Krzysztof Wiktorowicz; Henryk Wysocki Journal: Arch Med Sci Date: 2013-02-10 Impact factor: 3.318
Authors: William T Andrews; Deborah Donahue; Adam Holmes; Rashna Balsara; Francis J Castellino; Amanda B Hummon Journal: Anal Bioanal Chem Date: 2020-02-28 Impact factor: 4.142